Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration’s Adverse Event Reporting System.

April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
Copyright © Ark Medical Solutions Inc. All Rights Reserved.